Palisade Bio (PALI) Short term Debt (2010 - 2025)
Palisade Bio (PALI) reported Short term Debt of $235000.0 for Q3 2025, up 256.06% on a QoQ basis from $66000.0 in Q2 2025.
Palisade Bio (PALI) has 11 years of Short term Debt data on file, last reported at $235000.0 in Q3 2025.
- Quarterly Short term Debt changed N/A year-over-year to $235000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $235000.0 (changed N/A YoY) and the FY2023 annual result came in at $143000.0, changed N/A from the prior year.
- Short term Debt advanced to $235000.0 in Q3 2025 per PALI's latest filing, from $66000.0 in the prior quarter.
- Across five years, Short term Debt topped out at $1.1 million in Q2 2021 and bottomed at $66000.0 in Q2 2025.
- The 4-year median for Short term Debt is $143000.0 (2023), against an average of $254125.0.
- The widest annual swing landed in 2021, when Short term Debt tumbled 91.69%; it then sank 51.75% in 2025.
- Tracing PALI's Short term Debt over 4 years: stood at $87000.0 in 2021, then jumped by 64.37% to $143000.0 in 2023, then grew by 4.2% to $149000.0 in 2024, then surged by 57.72% to $235000.0 in 2025.
- Per Business Quant, the three latest PALI Short term Debt figures stand at $235000.0 (Q3 2025), $66000.0 (Q2 2025), and $69000.0 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 235,000.00 |
| Jun 30, 2025 | 66,000.00 |
| Mar 31, 2025 | 69,000.00 |
| Jun 30, 2024 | 149,000.00 |
| Mar 31, 2024 | 143,000.00 |
| Dec 31, 2023 | 143,000.00 |
| Dec 31, 2021 | 87,000.00 |
| Jun 30, 2021 | 1.14 Mn |
| Dec 31, 2020 | 1.05 Mn |
| Mar 31, 2017 | 2.53 Mn |
| Dec 31, 2016 | 3.71 Mn |
| Sep 30, 2016 | 4.83 Mn |
| Jun 30, 2016 | 5.91 Mn |
| Mar 31, 2016 | 4.47 Mn |
| Dec 31, 2015 | 4.55 Mn |
| Sep 30, 2015 | 4.46 Mn |
| Jun 30, 2015 | 3.17 Mn |
| Mar 31, 2015 | 1.93 Mn |
| Dec 31, 2014 | 730,012.00 |
| Jun 30, 2014 | 2.95 Mn |
| Mar 31, 2014 | 2.85 Mn |
| Dec 31, 2013 | 2.76 Mn |
| Sep 30, 2013 | 1.31 Mn |
| Jun 30, 2013 | 1.24 Mn |
| Mar 31, 2013 | 510,666.00 |
| Dec 31, 2010 | 1.25 Mn |